Navigation Links
Psychemedics Corporation Announces Second Quarter Results

$0.17 Dividend Declared

ACTON, Mass., July 28 /PRNewswire-FirstCall/ -- Psychemedics Corporation (Amex: PMD) today announced second quarter financial results for the period ended June 30, 2008. The Company also announced a quarterly dividend of $0.17 per share payable to shareholders of record as of September 5, 2008 to be paid on September 19, 2008. This will be the Company's 48th consecutive quarterly dividend.

The Company's second quarter revenue was $6.2 million, down 4% as compared to $6.5 million in the second quarter of 2007. Net income was $1.0 million or $0.20 per diluted share, down 23% from $1.3 million or $0.25 per share for the same period in 2007. The Company's revenue for the six months ended June 30, 2008 was $11.9 million, down 2% as compared to $12.2 million for the comparable period of 2007. Net income for the six months ended June 30, 2008 was $1.9 million or $0.36 per diluted share, a decrease of 19% over the comparable period last year during which the Company earned $2.4 million or $0.45 per share.

Raymond C. Kubacki, Chairman and Chief Executive Officer, said, "The jobs market remains a challenge, as the economy continues to see significant job losses through June -- in fact, six months of declines in a row. However, our revenues were off only slightly due to the fact that we continue to add new clients, thereby offsetting the weakness in hiring."

Kubacki continued, "We continue to make the investments in our sales and marketing in order to capitalize on significant future growth opportunities. This increased expense, as well as an increase in our legal expenses as compared to the same period last year, have caused our net income to be below our historic levels. However, despite these investments, we continue to report strong margins and strong earnings in a tough economic environment."

Kubacki concluded, "The Company continues to have a strong balance sheet with approximately $9.5 million of cash and investments and no long-term debt. We continue to stay focused and we remain confident in our future growth. Therefore, we are declaring our 48th consecutive quarterly dividend. This dividend demonstrates our Directors' confidence in the future and continued commitment to rewarding shareholders as we move forward."

On March 17, 2008, the Company announced the authorization of a 250,000 share stock repurchase program.

Psychemedics is the world's largest provider of hair testing for drugs of abuse with thousands of corporations relying on the patented Psychemedics drug testing services. Psychemedics' clients include over 10% of the Fortune 500, some of the largest police departments in America and six Federal Reserve Banks.

Financial Summary:

-- Revenue for the second quarter of $6.2 million, down 4% from the prior

year quarter

-- Revenue for the six month period of $11.9 million, down 2% from the

prior year period

-- Pretax income for the second quarter of $1.7 million, down 22% from the

prior year quarter

-- Pretax income for the six month period of $3.2 million, down 18% from

the prior year period

-- Net income for the second quarter of $1.0 million, or $0.20 per diluted

share, down 23% from the prior year quarter

-- Net income for the six month period of $1.9 million, or $0.36 per

diluted share, down 19% from the prior year period

The Psychemedics web site is

Cautionary Statement for purposes of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995: From time to time, information provided by Psychemedics may contain forward-looking information that involves risks and uncertainties. In particular, statements contained in this release that are not historical facts (including but not limited to statements concerning earnings, earnings per share, revenues, dividends, future business, growth opportunities, new accounts, customer base, market share, test volume and sales and marketing strategies) may be "forward looking" statements. Actual results may differ from those stated in any forward-looking statements. Factors that may cause such differences include but are not limited to risks associated with the expansion of the Company's sales and marketing team, development of markets for new products and services offered, the economic health of principal customers of the Company, government regulation, including but not limited to FDA regulations, competition and general economic conditions and other factors disclosed in the Company's filings with the Securities and Exchange Commission.

Contact: Jennifer Chmieleski

Vice President and Controller

(978) 206-8220



(in thousands, except per share amounts)


Three Months Ended Six Months Ended

June 30, June 30,

2008 2007 2008 2007

Revenue $6,211 $6,497 $11,920 $12,214

Cost of revenue 2,435 2,387 4,822 4,842

Gross profit 3,776 4,110 7,098 7,372


General and administrative 1,095 1,029 2,117 1,861

Marketing and selling 902 807 1,701 1,512

Research and development 120 161 238 256

2,117 1,997 4,056 3,629

Operating income 1,659 2,113 3,042 3,743

Interest income 73 101 185 197

Income before income taxes 1,732 2,214 3,227 3,940

Provision for income taxes 699 882 1,304 1,573

Net income $1,033 $1,332 $1,923 $2,367

Basic net income per share $0.20 $0.26 $0.37 $0.46

Diluted net income per share $0.20 $0.25 $0.36 $0.45

Dividends declared per share $0.17 $0.15 $0.32 $0.275

Weighted average common shares

outstanding, basic 5,224 5,172 5,222 5,191

Weighted average common shares

outstanding, diluted 5,279 5,237 5,277 5,260



(in thousands, except per share amounts)

June 30, December 31,

2008 2007



Current assets

Cash and cash equivalents $7,118 $6,097

Short-term investments 200 3,875

Accounts receivable, net of allowance for

doubtful accounts of $238 in 2008 and

$235 in 2007 3,876 3,555

Prepaid expenses and other current assets 955 499

Deferred tax assets 491 429

Total current assets 12,640 14,455

Property and equipment

Equipment and leasehold improvements, at cost 10,838 10,793

Less - Accumulated depreciation and amortization (10,143) (9,977)

695 816

Deferred tax asset 231 231

Long-term investments 2,200 -

Other assets 77 59

Total assets $15,843 $15,561


Current liabilities:

Accounts payable $583 $489

Accrued expenses 965 951

Deferred revenue 193 243

Total current liabilities 1,741 1,683

Shareholders' equity:

Preferred stock, $0.005 par value; 873 shares

authorized, no shares issued or outstanding - -

Common stock, $0.005 par value; 50,000 shares

authorized, 5,843 shares issued in 2008 and

5,812 shares issued in 2007 29 29

Paid-in capital 26,897 26,540

Less - Treasury stock, at cost, 610 shares in

2008 and 586 shares in 2007 (9,545) (9,164)

Accumulated deficit (3,279) (3,527)

Total shareholders' equity 14,102 13,878

Total liabilities and shareholders' equity $15,843 $15,561

SOURCE Psychemedics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Psychemedics Corporation Announces First Quarter Results
2. Psychemedics Corporation Announces Year End Results Record Annual and Quarterly Revenue
3. Jennifer Chmieleski Joins Psychemedics Corporation as Top Financial Officer
4. Psychemedics Corporation Joins Accenture in Co-Sponsoring Innovative Chief Talent Officer Book
5. HealthFitness Corporation to Report Second Quarter Financial Results
6. Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options
7. Digirad Corporation Reports Financial Results for 2008 Second Quarter and Six Months
8. minSURG(TM) Corporation Launches International Division
9. Baxa Corporation Launches New Electronic Users Group Web Site
10. Leatt Corporation To Sponsor 2008 South African Motocross Grand Prix
11. China Medicine Corporation Obtains Australian Patent for rADTZ
Post Your Comments:
(Date:11/27/2015)... Raleigh, NC (PRWEB) , ... November 27, 2015 , ... ... most effective ways to treat it. Surviving Mesothelioma has just posted the findings ... Researchers at University Hospital Zurich analyzed the cases of 136 mesothelioma patients who were ...
(Date:11/27/2015)... ... November 27, 2015 , ... The print component ... Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation of ... distributed nationally, through a vast social media strategy and across a network of ...
(Date:11/27/2015)... Wilmington, DE (PRWEB) , ... November 27, 2015 ... ... a member of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as ... is an independent group of Microsoft Dynamics SL software users, partners, industry experts ...
(Date:11/27/2015)... Los Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... the Commission on Accreditation of Allied Health Education Programs (CAAHEP) awarded accreditation to its ... exclusive list of CAAHEP accredited colleges, as only one of twelve colleges and universities ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., ... the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 ... brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive not ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... November 26, 2015 --> ... use SyMRI to find optimal contrast weighting of MRI ... and has signed a research agreement with SyntheticMR in order ... Using SyMRI, it is possible to generate multiple contrast images ... the patient has left, thus making it possible to both ...
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 ... the addition of the "2016 Future Horizons ... Monitoring (TDM) Market: Supplier Shares, Country Segment Forecasts, ... offering. --> ... comprehensive analysis of the Japanese therapeutic drug monitoring ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "2016 Future ... Drugs of Abuse Testing Market: Supplier Shares, ... report to their offering. --> ... of the "2016 Future Horizons and ...
Breaking Medicine Technology: